Potential effect of Imatinib on some sex hormones for male patients of Chronic Myelogenous Leukemia in Baghdad province

Ahmed, Abeer Anwer; Khaleel, Khaleed J; Fadhel, Alaa Abbas

doi:10.21931/rb/2021.06.04.9

Cited by 3 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study from China has observed that males ( n = 48) with CML‐CP on imatinib exhibited reduced sperm density, counts, activity and survival rates similar to our findings. The authors also reported normal testosterone and inhibin B serum levels in their study 46 contrary to the study from adults with CML‐CP on imatinib with decreased testosterone levels 47,48 . In this cohort, decreased testosterone levels were noted in 5 (7.5%) patients.…”

Section: Discussionmentioning

confidence: 56%

“…The authors also reported normal testosterone and inhibin B serum levels in their study 46 contrary to the study from adults with CML-CP on imatinib with decreased testosterone levels. 47,48 In this cohort, decreased testosterone levels were noted in 5 (7.5%) patients. Although there is limited availability of long-term data regarding the effects of imatinib on puberty and infertility in children, our study demonstrates that a notable proportion of children had experienced adverse effects on puberty and male fertility.…”

Section: Discussionmentioning

confidence: 66%

See 1 more Smart Citation

Treatment and follow‐up of children with chronic myeloid leukaemia in chronic phase (CML‐CP) in the tyrosine kinase inhibitor (TKI) era—Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort

Roy Moulik,

Keerthivasagam,

Pandey

et al. 2023

Br J Haematol

View full text Add to dashboard Cite

SummaryTyrosine kinase inhibitors (TKIs) have drastically improved the outcomes of pCML (paediatric CML) but data on long‐term off‐target toxicities of TKIs in children are scarce. In this single‐centre, retrospective cum prospective study of pCML in chronic phase, we report our experience of treating 173 children with imatinib and following them for long‐term toxicities. Mean (SD) time to attain CHR, CCyR and MMR were 3.05 (2.1), 10.6 (8.4) and 43.4 (31.8) months respectively. DMR was not attained in 59 (34%) patients at last follow‐up. Ten patients were switched to second‐generation TKIs (2G‐TKIs; nilotinib = 1/dasatinib = 9) due to poor/loss in response, of which seven had kinase domain mutations. Three patients progressed to the blastic phase. At a median follow‐up of 84 (3–261) months, the 5‐year EFS and OS for the entire cohort were 96.9% (95% CI: 93.4–100) and 98.7% (95% CI: 96.9–100) respectively. Screening for long‐term toxicities revealed low bone density and hypovitaminosis D in 70% and 80% respectively. Other late effects included short stature (27%), delayed puberty (15%), poor sperm quality (43%) and miscellaneous endocrinopathies (8%). Children younger than 5 years at diagnosis were more susceptible to growth and endocrine toxicities (p = 0.009). Regular monitoring for long‐term toxicities, timely intervention and trial of discontinuation whenever feasible are likely to improve the long‐term outlook of pCML.

show abstract

Section: Discussionmentioning

confidence: 56%

Section: Discussionmentioning

confidence: 66%

Treatment and follow‐up of children with chronic myeloid leukaemia in chronic phase (CML‐CP) in the tyrosine kinase inhibitor (TKI) era—Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort

Roy Moulik,

Keerthivasagam,

Pandey

et al. 2023

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…11 Young patients, regardless of prognostic factors, are generally well. [12][13][14] Globally, CML's incidence and death cases increased slightly in males whereas decreasing in females. 15 Imatinib, a tyrosine kinase inhibitor (TKI), inhibits the proliferation of CML lines by inhibiting BCR-ABL kinase activity and is currently being used for the treatment of CML.…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological features and risk stratification by the sokal score of patients with chronic myeloid leukemia at a tertiary care hospital in North-East India: A prospective study

Anjanjyoti Rajkonwar,

Upam Kumar Sharma,

Sima Sonowal

et al. 2024

Asian J Med Sci

View full text Add to dashboard Cite

Background: Chronic myeloid leukemia (CML) is a hematologic malignancy characterized by excessive growth of myeloid cells and their progenitors. The incidence of CML is approximately 1–2/100,000 population per year. Aims and Objectives: The aims and objectives of the study are to determine the clinicopathological features of patients with CML and their risk stratification by the Sokal score at a tertiary care hospital in North-East India. Materials and Methods: This was a single-center prospective study conducted for 5 years (2018–2022). A total of 109 cases diagnosed with CML by qualitative analysis of BCR-ABL1 transcript reverse transcription-polymerase chain reaction were included in the study. The Sokal score was calculated using previously published formulae to classify the patients into different risk groups. The outcome (dead or alive) of CML patients was compared with their individual risk groups using Fisher’s exact test. Results: Out of 109 CML patients, 73 were males and 36 were females. At the end of the study, 85 patients were alive whereas 24 died. The mean age at presentation was 42.08±15.06 years. The pediatric age group comprises 1.84% of total cases. The percentages of death were higher (79.17%) in patients aged 18–59 years, followed by 20.83% in ≥60 years age group, whereas no death was recorded in the pediatric age group (<18 years). The abdominal hard lump was the most common clinical presentation, followed by abdominal fullness, weakness, and pain abdomen. The Sokal score assigns the majority (66.06%) of patients to the intermediate risk (IR) category, followed by 25.69% and 8.26% in the high-risk (HR) and low-risk (LR) categories, respectively. It was observed that the majority (28.57%) of patients died in the HR group, followed by 20.83% in the IR group and 11.11% in the LR group. Conclusion: The mean age of CML patients is lower than that observed in many Western countries. The Sokal score assigns the majority of patients to IR category and the maximum death were seen in the HR group.

show abstract

Chronic Myeloid Leukemia: A retrospective study of clinical and pathological features

Ahmed

Khaleel

Fadhel

et al. 2022

Self Cite

View full text Add to dashboard Cite

Chronic myeloid leukemia (CML), is one of the myeloproliferative disorders with a characteristic cytogenetic abnormality resulting in the BCR-ABL fusion gene. Imatinib Mesylate is an effective agent for treating patients in all stages of CML. According to the annual Iraqi cancer registry 2019, the total number of chronic myeloproliferative disorders was 338. The percentage and incidence rates were 0.94% and 0.86%, respectively, with a higher incidence rate in males than females (1.12 in males and 0.60 in females). In this registry, no details about CML, so this study aimed to estimate the number of CML patients who attended the national center of hematology from 2005 until 2020 and investigate their epidemiological and clinic-pathological data. All data were obtained from the National Center of Hematology /Baghdad. Data regarding annual admission, number of deaths, and information about age, regions, and sex, were collected from patient cards. Interview and history taking from the patient and reviewing their clinical features at diagnosis were performed, and then statistical analysis was achieved. Two hundred sixteen patients were registered as CML; among them, 163 are still alive, while 53 died. The mean age at diagnosis was 40.39 ±14.30, with a male-to-female ratio of 1:1.16. The pediatrics age group comprises 3.7% of total cases and 1.8 % and 9.4% in the alive and dead groups, respectively. The percentages of death were higher in the pediatric age group, 62,5%( 5 /8), followed by the patient group who were ≥60 years, 42.1%(8/19), while it was the least in adults < 60 years, 21.1% (40/189). In conclusion, the studied patients with CML were younger than the globally reported ages at diagnosis, with predominant female patients. Females had better survival, while children and the elderly were the worse. Most patients were symptomatic at diagnosis; however, a good outcome is achieved when treated with IM. Keywords: CML, Imatinib, leukemia,

show abstract

Potential effect of Imatinib on some sex hormones for male patients of Chronic Myelogenous Leukemia in Baghdad province

Cited by 3 publications

References 25 publications

Treatment and follow‐up of children with chronic myeloid leukaemia in chronic phase (CML‐CP) in the tyrosine kinase inhibitor (TKI) era—Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort

Treatment and follow‐up of children with chronic myeloid leukaemia in chronic phase (CML‐CP) in the tyrosine kinase inhibitor (TKI) era—Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort

Clinicopathological features and risk stratification by the sokal score of patients with chronic myeloid leukemia at a tertiary care hospital in North-East India: A prospective study

Chronic Myeloid Leukemia: A retrospective study of clinical and pathological features

Contact Info

Product

Resources

About